C4 Therapeutics (CCCC)
(Delayed Data from NSDQ)
$6.50 USD
+0.06 (0.93%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $6.49 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
CCCC 6.50 +0.06(0.93%)
Will CCCC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CCCC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CCCC
Community Health Systems (CYH) Reports Q2 Loss, Tops Revenue Estimates
C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?
CCCC: What are Zacks experts saying now?
Zacks Private Portfolio Services
C4 Therapeutics (CCCC) Upgraded to Buy: Here's Why
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates
Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline
Other News for CCCC
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day
C4 Therapeutics: Losing Steam And Presenting An Opportunity
C4 Therapeutics Appoints Mr. Cooper to Board
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors